Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses, suggesting immunity will be long-lasting.

29 Jun, 2021 | 10:03h | UTC

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature

Commentaries: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical

Related: A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.

 

Commentary on Twitter (thread – click for more)

 

Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.

29 Jun, 2021 | 10:07h | UTC

Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine

Commentary: Expert reaction to case report of from the U.S. of thrombosis with thrombocytopenia after the Moderna mRNA vaccine – Science Media Centre

 

[Preprint] 3rd AstraZeneca shot gives strong immunity.

29 Jun, 2021 | 10:01h | UTC

Study: 3rd AstraZeneca shot gives strong immunity – Reuters

Original Study (preprint): Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) – SSRN/The Lancet

 

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

29 Jun, 2021 | 10:00h | UTC

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – Clinical Infectious Diseases

Related: Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

 

The COVID pandemic’s lingering impact on clinical trials – “Medical researchers are beginning to shift their focus away from COVID-19 — but the pandemic could continue to affect studies focused on other diseases.”

29 Jun, 2021 | 09:57h | UTC

The COVID pandemic’s lingering impact on clinical trials – Nature

 

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

28 Jun, 2021 | 10:01h | UTC

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet

Commentaries: Heterologous vaccine regimens against COVID-19 – The Lancet AND

 

Commentary on Twitter (thread – click for more)

 

WHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads.

28 Jun, 2021 | 09:55h | UTC

WHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads – CNBC

 

Commentary on Twitter (thread – click for more)

 

Delta “Plus”: Scientists say too early to tell risk of Covid-19 variant.

28 Jun, 2021 | 09:53h | UTC

Delta plus India: Scientists say too early to tell risk of Covid-19 variant – BBC

See also: There are at least 200 known cases of the Delta Plus coronavirus variant worldwide. Here’s what we know – CNN

Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.

28 Jun, 2021 | 09:52h | UTC

Is one vaccine dose enough if you’ve had COVID? What the science says – Nature

Related: Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.

 

Commentary on Twitter

 

Study finds 96.1% of patients objectively recovered from anosmia 1 year after COVID-19 diagnosis.

28 Jun, 2021 | 09:49h | UTC

Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis – JAMA Network Open

Commentary: Did Covid-19 take your taste and smell? Here’s when they may return – CNN AND Lost Sense of Smell Returns for Almost All COVID Survivors – HealthDay

 

WHO: Delta variant is ‘most transmissible’ identified so far.

28 Jun, 2021 | 09:58h | UTC

WHO: Delta variant is ‘most transmissible’ identified so far – Associated Press

Related: Delta COVID variant fuels global surges, complicates reopenings – CIDRAP AND Delta variant triggers dangerous new phase in the pandemic – Science AND Delta coronavirus variant: scientists brace for impact – Nature AND Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv AND COVID-19: The rise and rise of Delta – Sciblogs AND Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”.

 

IDSA Updated Covid-19 Guidance: Co-Infection and Antimicrobial Stewardship – “bacterial coinfections with SARS-CoV-2 infection are relatively infrequent (likely occurring in less than 10% of hospitalized COVID-19 patients)”.

28 Jun, 2021 | 09:51h | UTC

Co-Infection and Antimicrobial Stewardship – Infectious Diseases Society of America

Related: Another study shows a high frequency of antibiotic use among patients hospitalized with Covid-19 (85.2%), despite low rates of confirmed secondary bacterial infections.

 

[Preprint] Long Covid: Third of people infected have long term symptoms.

25 Jun, 2021 | 10:30h | UTC

Covid-19: Third of people infected have long term symptoms – The BMJ

Original study (preprint): Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people – Imperial College London

 

Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.

25 Jun, 2021 | 10:37h | UTC

Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis – Intensive Care Medicine

 

Commentary on Twitter

 

No evidence yet to suggest Covid vaccine booster is needed, CDC group says.

25 Jun, 2021 | 10:29h | UTC

No evidence yet to suggest Covid vaccine booster is needed, CDC group says – NBC News

Related opinion: 7 Reasons Why We Should Not Need Boosters for COVID-19 – by Monica Ghandi, MD

 

Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.

25 Jun, 2021 | 10:33h | UTC

Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds – The University of Bergen

Original Study: Long COVID in a prospective cohort of home-isolated patients – Nature Medicine

 

Commentary on Twitter

 

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

25 Jun, 2021 | 10:24h | UTC

The mRNA Vaccines Are Extraordinary, but Novavax Is Even Better – The Atlantic

Related: (Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

 

Commentary on Twitter

https://twitter.com/hildabast/status/1408175034879733761

 

RCT: Doxycycline for 7 days superior to single-dose azithromycin for the treatment of rectal chlamydia infection.

25 Jun, 2021 | 10:19h | UTC

Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Doxycycline Superior to Azithromycin for Asymptomatic Rectal Chlamydia in Men – Physician’s Weekly

 

Commentary on Twitter

 

Delta COVID variant fuels global surges, complicates reopenings.

25 Jun, 2021 | 10:23h | UTC

Delta COVID variant fuels global surges, complicates reopenings – CIDRAP

 

Perspective | Are Chinese COVID vaccines underperforming? a dearth of real-life studies leaves unanswered questions.

25 Jun, 2021 | 10:26h | UTC

Are Chinese COVID Vaccines Underperforming? A Dearth of Real-Life Studies Leaves Unanswered Questions – Health Policy Watch

Related: WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. AND Brazilian town experiment shows mass vaccination can wipe out COVID-19.

 

IDSA 2021 focused update guidelines on the management of Clostridioides difficile infection in adults.

25 Jun, 2021 | 10:17h | UTC

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults – Clinical Infectious Diseases

News release: IDSA And SHEA Release New Guidelines for Managing Clostridium Difficile Infection – Infectious Diseases Society of America

 

Commentary on Twitter

 

Perspective | Why are people with obesity more vulnerable to COVID?

25 Jun, 2021 | 10:21h | UTC

Why Are People with Obesity More Vulnerable to COVID? – Scientific American

 

CDC advisory panel backs use of dengue vaccine in high-risk areas, despite delivery challenges.

25 Jun, 2021 | 10:13h | UTC

CDC advisory panel backs use of dengue vaccine in high-risk areas, despite delivery challenges – STAT

 

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients can improve the immunogenicity of the vaccine.

24 Jun, 2021 | 10:32h | UTC

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients – New England Journal of Medicine

 

Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.

24 Jun, 2021 | 10:38h | UTC

Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses – ACS Nano

Related: France recommends single dose of vaccine if previous Covid infection detected. AND [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.